Brokers Offer Predictions for Tourmaline Bio Q2 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Tourmaline Bio in a note issued to investors on Monday, May 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s Q3 2025 earnings at ($1.00) EPS and Q4 2025 earnings at ($0.96) EPS.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.02.

Several other brokerages have also issued reports on TRML. Wedbush lifted their price target on Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a research note on Friday, March 14th. Chardan Capital reaffirmed a “buy” rating and issued a $70.00 target price on shares of Tourmaline Bio in a research note on Monday. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Tourmaline Bio in a research note on Monday. Finally, Lifesci Capital started coverage on shares of Tourmaline Bio in a research note on Monday, February 24th. They issued an “outperform” rating and a $58.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tourmaline Bio currently has a consensus rating of “Buy” and an average target price of $49.33.

Tourmaline Bio Stock Performance

NASDAQ TRML opened at $15.39 on Wednesday. Tourmaline Bio has a 52-week low of $11.56 and a 52-week high of $29.79. The company has a fifty day moving average of $15.36 and a 200-day moving average of $18.95. The company has a market capitalization of $395.29 million, a P/E ratio of -5.46 and a beta of 2.11.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TRML. SG Americas Securities LLC lifted its holdings in Tourmaline Bio by 3.9% in the 1st quarter. SG Americas Securities LLC now owns 36,180 shares of the company’s stock worth $550,000 after buying an additional 1,368 shares during the period. GAMMA Investing LLC boosted its position in shares of Tourmaline Bio by 4,481.7% during the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company’s stock valued at $114,000 after purchasing an additional 7,350 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Tourmaline Bio by 4.3% in the 4th quarter. Wellington Management Group LLP now owns 68,599 shares of the company’s stock worth $1,391,000 after acquiring an additional 2,858 shares in the last quarter. California State Teachers Retirement System grew its holdings in Tourmaline Bio by 527.9% in the fourth quarter. California State Teachers Retirement System now owns 10,505 shares of the company’s stock worth $213,000 after purchasing an additional 8,832 shares during the period. Finally, Woodline Partners LP increased its stake in shares of Tourmaline Bio by 1.6% during the fourth quarter. Woodline Partners LP now owns 161,721 shares of the company’s stock valued at $3,280,000 after purchasing an additional 2,567 shares in the last quarter. 91.89% of the stock is owned by hedge funds and other institutional investors.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.